618 related articles for article (PubMed ID: 26433783)
1. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA;
J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783
[TBL] [Abstract][Full Text] [Related]
2. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
[TBL] [Abstract][Full Text] [Related]
3. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis.
De Waele J; Carlier M; Hoste E; Depuydt P; Decruyenaere J; Wallis SC; Lipman J; Roberts JA
Minerva Anestesiol; 2014 Dec; 80(12):1302-9. PubMed ID: 24762706
[TBL] [Abstract][Full Text] [Related]
4. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Yusuf E; Spapen H; Piérard D
J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
[TBL] [Abstract][Full Text] [Related]
9. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
Cies JJ; Shankar V; Schlichting C; Kuti JL
Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
[TBL] [Abstract][Full Text] [Related]
11. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
13. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
[TBL] [Abstract][Full Text] [Related]
15. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
Alobaid AS; Brinkmann A; Frey OR; Roehr AC; Luque S; Grau S; Wong G; Abdul-Aziz MH; Roberts MS; Lipman J; Roberts JA
J Antimicrob Chemother; 2016 Mar; 71(3):696-702. PubMed ID: 26702922
[TBL] [Abstract][Full Text] [Related]
16. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
17. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
Mah GT; Mabasa VH; Chow I; Ensom MH
Ann Pharmacother; 2012 Feb; 46(2):265-75. PubMed ID: 22274145
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
Shotwell MS; Nesbitt R; Madonia PN; Gould ER; Connor MJ; Salem C; Aduroja OA; Amde M; Groszek JJ; Wei P; Taylor ME; Tolwani AJ; Fissell WH
Clin J Am Soc Nephrol; 2016 Aug; 11(8):1377-1383. PubMed ID: 27197907
[TBL] [Abstract][Full Text] [Related]
20. Dose optimization of piperacillin/tazobactam in critically ill children.
De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
